Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Editas Medicine (EDIT) Tops Q4 EPS by 11c
February 24, 2022 6:40 AM ESTEditas Medicine (NASDAQ: EDIT) reported Q4 EPS of ($0.61), $0.11 better than the analyst estimate of ($0.72). Revenue for the quarter came in at $12.5 million versus the consensus estimate of $4.29 million.
For earnings history and earnings-related data on Editas Medicine (EDIT) click here.
... More